One of the difficulties is that there is no rapid-detection test for Ebola. OraSure is known for its rapid HIV tests, including the first in-home oral HIV test. HIV is caused by a virus. Ebola is a virus. OraSure also has a subsidiary that is a leader in oral-fluid-sample collection.
In terms of speculation, given OraSure's capabilities in virus detection, it stands to reason that OraSure would be exploring or working on an Ebola test. Please note that I have no confirmed information In this regard and the foregoing speculation may turn out to be entirely wrong.
The attraction of OraSure is that unlike other companies with even a remote connection to Ebola, OraSure stock has not run up. There is a strong support nearby that allows, from a trading perspective, close stops to control risk. On the positive side, if the company is able to show progress on an Ebola test, based on the price action in the other Ebola stocks, this stock can triple or quadruple quickly.
Another plus is that OraSure has a float of 48.91 million shares and 55.9 million shares outstanding. Also, 81% of stock is held by institutions. As of the last report, only 5.5% of the float was short.
The foregoing characteristics are important because they reduce the probability of wild price action akin to many of the currently favored Ebola stocks.